Cidara Therapeutics
Biotechnology company developing novel anti-infective therapies, including long-acting antifungal agents using its Cloudbreak® antiviral platform.
Website
https://www.cidara.comLocation
San Diego, California, USA
Founded
2013
Categories
biotech, anti-infectives, antifungal, therapeutics, infectious-disease
Notes
Cidara Therapeutics (NASDAQ: CDTX) is a biotechnology company focused on developing novel anti-infective therapies. The company's Cloudbreak® platform enables the development of long-acting drug-Fc conjugates that combine the targeting ability of antibodies with the potency of small molecule drugs.
Cidara's lead product rezafungin is a once-weekly echinocandin antifungal approved for the treatment of candidemia and invasive candidiasis. The company is also developing antiviral therapies using its Cloudbreak platform.
Team
- Jeffrey Stein, Ph.D. - President & Chief Executive Officer
- LinkedIn: linkedin.com/in/jeffreystein
- James Levine - Chief Financial Officer
Additional Research Findings
- NASDAQ: CDTX (publicly traded)
- Cloudbreak® drug-Fc conjugate platform
- Rezafungin (Rezzayo®) - FDA approved antifungal
- Focus on antifungal and antiviral therapies
- Long-acting anti-infective agents
- Headquarters in San Diego, California
- Backed by Bain Capital Life Sciences among other investors